Advertisement

Better programming for Boston Scientific's implantable cardiac devices would provide more accurate therapy and reduce mortality risk for patients, according to a company-sponsored study.

Boston Scientific logo

Changes to programming in pacemakers and defibrillators could significantly cut down on inappropriate shocking and reduce mortality risks for patients, according to a Boston Scientific (NYSE:BSX) study.

The medical device giant found that modified programming could reduce unnecessary shocks by more than 75% for patients with dual-chamber implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy defibrillators (CRT-D).

Advertisement
Advertisement